Next-Generation Cell Therapies
Part of the BTEC Fall 2021 Seminar Series
Friday, Oct. 8, 2021
Engineered T-cell therapies have had remarkable success in clinical use, more than doubling the median survival time of patients with blood cancers. However, these highly personalized cell therapies cost upwards of $750,000 and carry significant safety risks. In this presentation, Dr. Jasmine Edelstein will discuss how recent advances in CRISPR gene editing are addressing these shortcomings and broadening cell-therapy applications beyond oncology.
Jasmine Edelstein, Ph.D.
Scientist, Be Biopharma
About the presenter
Dr. Edelstein is a bioengineer with expertise in immune cell engineering. At Be Biopharma, she engineers B cells for rare diseases and oncology applications.
Earlier this year, Dr. Edelstein earned a PhD in biomedical engineering from the Joint Department of Medical Engineering that is affiliated with the University of North Carolina at Chapel Hill and NC State. Prior to her current role at Be Biopharma, she completed an internship at Editas Medicine, where she worked on engineered T cells, NK cells, and iPSCs for oncology applications. In 2014, she earned a Bachelor of Engineering in chemical and biological engineering from Princeton University.